440 filings
Page 4 of 22
DEFA14A
dijeqgnr gn
24 Jun 22
Additional proxy soliciting materials
4:24pm
DEFA14A
xdr7385dr76d 4uoh0y
14 Jun 22
Additional proxy soliciting materials
4:05pm
8-K
wiclrlxvc1bpw0bd 8i
6 Jun 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
DEFA14A
uj1d912nqfj
31 May 22
Additional proxy soliciting materials
4:52pm
8-K
kh2hn6hlsu dkediufc
27 May 22
Regulation FD Disclosure
8:44am
NT 10-K
9m4p4v1tqa8xif7
31 Mar 22
Notice of late annual filing
4:49pm
8-K
d5q2w 0w0crgkd
12 Jan 22
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
10:08am
8-K
e1ga2b w5qufs4b
10 Jan 22
Regulation FD Disclosure
6:02am
8-K
b5wj95 v5g1egxs0
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
m9warthk1t53
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
aoq5sf4h51 d2ae42
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
EFFECT
xjj9fj1j
26 Nov 21
Notice of effectiveness
12:15am
CORRESP
9ssomze 8cb
22 Nov 21
Correspondence with SEC
12:00am
8-K
cgk03 pcl0rwlpp
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am